A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-3792 Injection
Maximum tolerated dose (MTD), From the first dose of study medication up to 21 days.|Recommended phase â…¡ dose (RP2D), From the first dose of study medication up to 21 days.|Incidence of dose limited toxicity (DLT), From the first dose of study medication up to 21 days.|Adverse events (AEs), Up to 24 weeks.|Serious adverse events (SAEs), Up to 24 weeks.
Objective response rate (ORR), Up to 6 months.
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.